Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies. In the present experiments, dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye blinking in squirrel monkeys. Additional comparisons were made with the effects of D2 receptor agonists and indirect dopamine agonists. The results show that D1 agonists increased eye blinking in an efficacy-related manner, whereas the D1 receptor blocker SCH 39166 [(-)-trans-6,7,7alpha,8,9,13beta-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho[2,1-b]azepine] only decreased rates of eye blinking. D1 high-efficacy agonists induced rates of eye blinking that were 2- to 3-fold greater than observed with dopamine D2 agonists and indirect agonists. In drug combination experiments, increases in eye blinking induced by the D1 high-efficacy agonist R-(+)-6-Br-APB [R-(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] were antagonized by both the D1 antagonist SCH 39166 and the lower efficacy agonist SKF 83959 [6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide], consistent with dopamine D1 receptor mediation of these behavioral effects. The dopamine D2 agonist (+)-PHNO [(+)-N-propyl-hydroxynaphthoxazine], which selectively activates dopamine D2 receptors, also attenuated D1 agonist-induced increase in eye blinking, suggesting that D2 receptor actions may inhibit D1-mediated increases in eye blinking. Overall, eye blink rate appears to be a robust behavioral measure that can be used to measure changes in dopaminergic D1 signaling and as a functional assay of agonist efficacy at dopamine D1 receptors.
McLean Hospital, 115 Mill Street, Belmont MA 02478, USA.
Emily M
EM
Jutkiewicz
Jack
J
Bergman
D000818:Animals; D001767:Blinking / Q000187:drug effects*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008024:Ligands; D010078:Oxazines / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000187:drug effects*; D012453:Saimiri
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors; D008024:Ligands; D010078:Oxazines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C042631:naxagolide